Status:

TERMINATED

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Lead Sponsor:

Ra Pharmaceuticals

Conditions:

Immune Mediated Necrotizing Myopathy

Eligibility:

All Genders

18-75 years

Phase:

PHASE2

Brief Summary

The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio to receive daily ...

Eligibility Criteria

Inclusion

  • Clinical diagnosis of IMNM (Immune-Mediated Necrotizing Myopathy)
  • Positive serology for anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) or anti-signal recognition particle (SRP) autoantibodies
  • Clinical evidence of weakness (≤ grade 4 out of 5) on manual muscle testing in at least one proximal limb muscle group
  • Creatine kinase (CK) of \>1000 U/L at Screening
  • No change in corticosteroid dose for at least 30 days prior to Baseline or anticipated to occur during the first 8-weeks on study
  • No changes in immunosuppressive therapy, including dose, for at least 30 days prior to Baseline or anticipated to occur during the first 8-weeks on study

Exclusion

  • History of meningococcal disease
  • Current or recent systemic infection within 2 weeks prior to Screening or infection requiring intravenous (IV) antibiotics within 4 weeks prior to Screening
  • Recent initiation of intravenous immunoglobulin (IVIG) (i.e., first cycle administered less than 90 days prior to Baseline)
  • Rituximab use within 90 days prior to Baseline or anticipated to occur during study
  • Statin use within 30 days prior to Baseline or anticipated to occur during study
  • Plasma exchange within 4 weeks prior to Baseline or expected to occur during the 8-week Treatment Period

Key Trial Info

Start Date :

November 7 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 14 2021

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT04025632

Start Date

November 7 2019

End Date

June 14 2021

Last Update

July 27 2022

Active Locations (18)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (18 locations)

1

University of California Los Angeles

Los Angeles, California, United States, 90095

2

University of California Irvine

Orange, California, United States, 92868

3

University of Florida Health Jacksonville

Jacksonville, Florida, United States, 32209

4

University of South Florida

Tampa, Florida, United States, 33612

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy | DecenTrialz